



Clinical trial opportunity

For dogs diagnosed with canine lymphoma and receiving chemotherapy

STUDY TITLE: "Improving GI function in cancer patients: the potential of metoclopramide to decrease vincristine-induced GI ileus"

Lymphoma is a common cancer in dogs, and the current standard of chemotherapy is the multi-agent CHOP protocol. This treatment involves a drug called vincristine, which can induce gastrointestinal (GI) ileus in the canine patient. This health issue can lead to nausea, decreased appetite and stomach upset.

This WCVI clinical trial's goal is to determine if metoclopramide, a drug that's commonly used to treat and prevent nausea, can alleviate the GI ileus due to vincristine.

Q. What do study participants receive?

All dogs enrolled in the clinical trial receive:

- complimentary flow cytometry
- MDR-1 testing (multi-drug sensitivity)
- abdominal ultrasound examination

Q. What dogs are eligible?

The research team is seeking dogs (all breeds and sizes) that have been diagnosed with multicentric lymphoma (substage a) and are pursuing the CHOP chemotherapy treatment protocol at the WCVI Veterinary Medical Centre.

Questions?

Please contact Dr. Arata Matsuyama (medical.oncology@usask.ca) for more details.



Photo: Caitlin Taylor.